OHSU
Return to Listing

187 result(s) for Liver

PI Name Protocol # Title
Robert Peterka IRB00000675 Sensorimotor Integration in Human Postural Control
Edward Neuwelt IRB00000922 Phase II Clinical Trial of Patients with High-Grade Glioma Treated with Intra-arterial Carboplatin-based Chemotherapy, Randomized to Treatment with or without Delayed Intravenous Sodium Thiosulfate as a Potential Chemoprotectant against Severe Thrombocytopenia
Edward Neuwelt IRB00001012 A Phase II Study of Patients with Newly Diagnosed Primary Central Nervous System Lymphoma Treated with Methotrexate/BBBD, and Adding Rituximab (an anti CD-20 Antibody) and Carboplatin, to the Treatment Regimen
Christopher Ryan IRB00001666 A Multicenter, Open-Label Single-Arm Study of YONDELIS (trabectedin) for Subjects With Locally Advanced or Metastatic Soft Tissue Sarcoma Excluding Leiomyosarcoma and Liposarcoma Who Have Relapsed or Are Refractory to Standard of Care Treatment
Eric Simpson IRB00002568 Pathogenesis of Skin Disease
Edward Neuwelt IRB00002868 Phase I/II Study of Carboplatin, Melphalan and Etoposide Phosphate in Conjunction with Osmotic Opening of the Blood-Brain Barrier and Delayed Intravenous Sodium Thiosulfate Chemoprotection, in Previously Treated Subjects with Anaplastic Oligodendroglioma or Oligoastrocytoma
Vassiliki Tsikitis IRB00003082 Oregon Colorectal Cancer Registry
David Koeller IRB00003120 A Global, Multi-Center, Long-Term, Observational Survey of Patients with Hunter Syndrome (Mucopolysaccharidosis II) - Hunter Outcome Survey (HOS)
William Rooney IRB00003290 MRI Protocol Development and Optimization
Brett Sheppard IRB00003609 Oregon Pancreas Tumor Registry
Ryan Olson IRB00003754 Hazard and Threat Detection
Shoukhrat Mitalipov IRB00003892 [STEM CELLS] Histocompatible human pluripotent cells
Fay Horak IRB00004131 Exercise, Brain Imaging, Cognition, and Gait in Parkinsonism
Tessa Marburger IRB00004753 A Global, Multi-Center, Longitudinal, Observational Survey of Patients with Documented Transthyretin (TTR) Mutations or Wild-Type TTR Amyloidosis.
Andrew Ahmann IRB00005023 TrialNet Natural History Study of the Development of Type 1 Diabetes
Edward Neuwelt IRB00005056 Phase I/II Study of Intra-arterial Melphalan Given with Intra-arterial Carboplatin, Osmotic Blood-Brain Barrier Disruption and Delayed Otoprotective Sodium Thiosulfate for Patients with Recurrent or Progressive CNS Embryonal or Germ Cell Tumors
Kevin Billingsley IRB00005222 Oregon Liver Tumor Registry
Damien Fair IRB00005239 Typical and Atypical Brain Development
Julie Graff IRB00005254 A Phase II Study of CTLA Blockade by Ipilimumab plus Androgen Suppression Therapy in Patients with an Incomplete Response to AST Alone for Metastatic Prostate Cancer
Tomasz Beer IRB00005688 A Phase II study of MAOA inhibitor plus docetaxel in patients currently receiving and progressing on docetaxel therapy
Kelvin MacDonald IRB00005956 Transepithelial Potential Difference Measurements in Patients with Unusual Variants of Cystic Fibrosis
Dennis Crawford IRB00006045 A Randomized Comparison of NeoCart to Microfracture for the Repair of Articular Cartilage Injuries in the Knee
Lina Reiss IRB00006069 Optimization of Cochlear Implants and Hearing Aids
Cynthia McEvoy IRB00006091 Assessing the Effect of Vitamin C on Infant Lung Function When Given to Pregnant Women Who Smoke
Jack Kron IRB00006168 Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation (CABANA) Trial
Stephen Chui IRB00006256 I-SPY 2 TRIAL: Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis 2
Joel Nigg IRB00006258 Longitudinal Brain Imaging Study of ADHD
Penelope Hogarth IRB00006459 The Parkinson's Progression Markers Initiative (PPMI)
Amie Peterson IRB00006482 PVAMC / OHSU D: The Effect of Vitamin D on Balance in Parkinson's Disease
William Rooney IRB00006509 Magnetic Resonance Imaging and Biomarkers for Muscular Dystrophy
Jean-Baptiste Roullet IRB00006790 Sterol and Isoprenoid Research Consortium (STAIR) Smith-Lemli-Opitz Syndrome: A Longitudinal Clinical Study of Patients Receiving Cholesterol Supplementation
Matthew Taylor IRB00006867 A Phase 1 Study of Oral Carboxyamidotriazole Orotate (CTO) Titrated as a Single Agent in Patients with Advanced or Metastatic Solid Tumors and Titrated in Combination Therapy with Temodar® in Patients with Glioblastom Multiforme
Peter Andersen IRB00006918 RTOG 0920: A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
Charles Keller IRB00007095 Childhood Cancer Registry for Familial and Sporadic Tumors (CCuRe-FAST)
Stephen Spurgeon IRB00007195 A Phase II Proof of Concept Trial to Study Kinase Inhibition in Relapsed/Refractory Acute Leukemias: Using a Comprehensive in Vitro Kinase Inhibitor Panel to Select Individualized Targeted Therapies
Barry Oken IRB00007364 Mindfulness Meditation in Chronic Stress
Christopher Ryan IRB00007404 PVAMC / OHSU: S0931 EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study
Gina Vaccaro IRB00007561 C80702: A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients With Resected Stage III Colon Cancer
Robert Peterka IRB00007619 Vestibular contribution to the control of human upright stance
Theresa Koppie IRB00007854 PVAMC / OHSU: S1011, A Phase III Surgical Trial to Evaluate the Benefit of a Standard versus an Extended Pelvic Lymphadenectomy Performed at Time of Radical Cystectomy for Muscle Invasive Urothelial Cancer
Christopher Ryan IRB00007943 A Randomized, Double-Blind Phase II, Study of Gemcitabine Alone or in Combination with Pazopanib for Refractory Soft Tissue Sarcoma
Gina Vaccaro IRB00008019 A Randomized, Double-Blind, Multi-Center Phase 3 Study of ADI-PEG 20 plus Best Supportive Care (BSC) versus Placebo plus BSC in Subjects with Advanced Hepatocellular Carcinoma (HCC) Who Have Failed Prior Systemic Therapy
Gary Takahashi IRB00008027 A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients with Solid Tumor or Hematologic Malignancy
John Vetto IRB00008070 E1609: A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon α-2b for Resected High-risk Melanoma
Peter Andersen IRB00008071 Corticosteroid Treatment for the Reduction of Postoperative Pain Following Transoral Robotic Surgery
Yolanda Ibarra IRB00008112 Clinical investigation of the new nanohybrid resin composite Venus Pearl in class 2 cavities- a multi-center study.
Joseph Quinn IRB00008122 Cerebrospinal Fluid Biomarker Discovery
Stephen Chui IRB00008158 PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment
Emma Scott IRB00008296 Phase I Infusional Cyclophosphamide and Pulse Dexamethasone With Rapamycin and Hydroxychloroquine in Patients With Relapsed or Refractory Myeloma
Paul Spellman IRB00008314 Personalized Breast Cancer Genomics Registry
Emma Scott IRB00008373 A Prospective, Longitudinal, Observational Study in Newly Diagnosed Multiple Myeloma Patients to Assess the Relationship between Patient Outcomes, Treatment Regimens and Molecular Profiles
Eric Simpson IRB00008446 Skin Barrier Function Assessment in Rare Diseases Caused by Abnormal Sterol and Isoprenoid Metabolism: A Pilot Study
Kerri Winters IRB00008560 Group Exercise Training for Functional Improvement after Treatment: The GET FIT Trial
Tomasz Beer IRB00008569 A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination with Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men with Metastatic Castrate Resistant Prostate Cancer
Philip Korthuis IRB00008575 PVAMC / OHSU J: Risky Decision Making in Methamphetamine Users: The Role of Opioid Blockade
Akram Khan IRB00008597 A Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Event Driven Study to Compare the Time to First Clinical Worsening in Subjects with Pulmonary Arterial Hypertension Receiving UT-15C in Combination with a PDE5-I or ERA Compared with a PDE5-I or ERA Alone
Julie Graff IRB00008787 A Phase 2 Study of Increased-Dose Abiraterone Acetate in Patients with Castration Resistant Prostate Cancer (CRPC)
Joshi Alumkal IRB00008791 The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men with Biochemically Relapsed Hormone Sensitive Prostate Cancer
Jonathan Fellers IRB00008874 PVAMC / OHSU J: Pilot study of the dose response of entacapone on methamphetamine induced interest, mood elevation, and reward
Sonemany Salinthone IRB00008908 PVAMC / OHSU: Elucidating the Mechanisms that Mediate the Effects of Lipoic Acid in Multiple Sclerosis
Fay Horak IRB00008979 Frontal Cortex and Gait Freezing in Parkinson's Disease: Rehabilitation Impact
Yen Tibayan IRB00008988 The Treatment of Coronary Artery Lesions Using the PRO-Kinetic Energy Cobalt-Chromium, Bare-Metal Stent (BIOHELIX-I)
Charles Thomas IRB00009013 A Study to Determine the Immune Profile of Rectal Adenocarcinoma and its Correlation with the Efficacy of Neoadjuvant Chemoradiotherapy
Jeremy Cetnar IRB00009059 National Lung Cancer Partnership- Lung Cancer Mutation Consortium
Stephen Chui IRB00009076 A phase III randomized, double blind, placebo controlled study of BKM120 with fulvestrant, in postmenopausal women with hormone receptor-positive HER2-negative AI treated, locally advanced or metastatic breast cancer who progressed on or after mTOR inhibitor based treatment
Laura Newell IRB00009141 Phase III, Multicenter, Randomized, Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients 60-75 Years of Age with Untreated High Risk (Secondary) Acute Myeloid Leukemia (AML).
Andrew Ahmann IRB00009157 Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)
Michael Shapiro IRB00009174 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome (Odyssey Outcomes)
Kristen Mackiewicz Seghete IRB00009182 Neural Mechanisms of Cognitive Inhibition in Youth with and without a Trauma History
Tomasz Beer IRB00009204 Radiologically Guided Biopsies of Metastatic Castration Resistant Prostate Cancer to Identify Adaptive Mechanisms of Resistance
Christopher Ryan IRB00009241 Randomized, Double-Blind Phase III study of Pazopanib vs Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Joshi Alumkal IRB00009259 Identifying Mechanisms of Resistance to Enzalutamide (MDV3100) Treatment in Men with Castration-Resistant Prostate Cancer
Michael Heinrich IRB00009264 CSTI571X2103: A dose-finding phase Ib multicenter study of imatinib in combination with the oral phosphatidyl-inositol 3-kinase (PI3K) inhibitor BYL719 in patients with gastrointestinal stromal tumor (GIST) who failed prior therapy with imatinib and sunitinib.
Winston Chamberlain IRB00009280 Randomized Clinical Trial of OCT-Guided Laser-Assisted Lemellar Anterior Keratoplasty in Adults for Keratoconus
Winston Chamberlain IRB00009282 Randomized Clinical Trial of OCT-Guided Laser-Assisted Lamellar Anterior Keratoplasty in Adults for Stromal Opacities
Saurabh Gupta IRB00009290 Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional MR (The COAPT Trial)
Charlotte Kubicky IRB00009340 Impact of Breast Conservation Surgery on Surgical Outcomes and Cosmesis in Patients with Multiple Ipsilateral Breast Cancers (MIBC)
Julie Graff IRB00009352 A phase 2, randomized, 3-arm study of abiraterone acetate alone, abiraterone acetate plus degarelix, a GnRH antagonist, and degarelix alone for patients with prostate cancer with a rising PSA or a rising PSA and nodal disease following definitive radical prostatectomy
Julie Graff IRB00009363 PVAMC / OHSU J: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate Cancer
Christopher Ryan IRB00009365 An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)
Richard Maziarz IRB00009375 A Phase 1-2 Dose Escalation Study Evaluating Safety and Feasibility of BPX-501 T Cells after Partially Mismatched, Related, T Cell-Depleted HSCT
Emma Scott IRB00009398 A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age
Roger Dailey IRB00009401 A multicenter, double-masked, placebo-controlled, efficacy and safety study of RV 001, an insulin-like growth factor-1 receptor (IGF-1R) antagonist antibody (fully human), administered every 3 weeks (q3W) by intravenous (iv) infusion in patients suffering from active thyroid eye disease (TED)
Gina Vaccaro IRB00009414 A Phase III Study of FOLFIRINOX with or without Hyperacute-Pancreas (Algenpantucel-L) Immunotherapy in Subjects with Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Kresimira Milas IRB00009420 Oregon Index of Endocrine Neoplasias (ORION)
Emma Scott IRB00009421 A Phase I Dose-Escalation Study of Carfilzomib in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis
Matthew Taylor IRB00009443 A Randomized Phase III, Open Label, Multicenter, Two-Arm Study Comparing the Efficacy of MEK162 versus Decarbazine in Patients with Advanced Unresectable or Metastatic NRAS Mutation-Positive Melanoma
Kevin Winthrop IRB00009463 The Oregon nontuberculous mycobacteria (NTM) cohort; immune correlates of pulmonary NTM disease progression
Christopher Ryan IRB00009464 A Phase II Study of Sorafenib with Chemotherapy, Radiation, and Surgery for High-Risk Soft Tissue Sarcomas
Matthew Taylor IRB00009480 A Randomized, Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients with Differentiated Thyroid Cancer
Tomasz Beer IRB00009497 LCCC 1231: Observational Longitudinal Study of Pain in Men with Metastatic Castrate-Resistant Prostate Cancer
Atulya Deodhar IRB00009498 A Multicenter, Randomized, Double-Blind, Study Comparing the Efficacy and Safety of Continuing Versus Withdrawing Adalimumab Therapy in Maintaining Remission in Subjects with Non-Radiographic Axial Spondyloarthritis
Jeremy Cetnar IRB00009512 A Phase II/III Randomized Trial of Two Doses of MK-3475 (SCH900475) versus Docetaxel in Previously Treated Subjects with Non-Small Cell Lung Cancer
Willscott Naugler IRB00009526 A randomized, double blind, placebo-controlled, multicenter phase III study of regorafenib in patients with hepatocellular carcinoma (HCC) after sorafenib
Matthew Taylor IRB00009531 A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib in Patients with Papillary or Poorly Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy
Christopher Ryan IRB00009553 A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects with Metastatic Renal Cell Carcinoma that has Progressed after Prior VEGFR Tyrosine Kinase Inhibitor Therapy
Brian Druker IRB00009554 A single-arm, multicenter, nilotinib treatment-free remission study in patients with BCR-ABL1 positive Chronic Myelogenous Leukemia in chronic phase who have achieved durable minimal residual disease (MRD) status on first line nilotinib treatment.
Stephen Spurgeon IRB00009556 A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination with Bendamustine and Rituximab (BR) in Subjects With Newly Diagnosed Mantle Cell Lymphoma
Dennis Crawford IRB00009557 A Stratified, Post-Market Study of DeNovo NT for Treatment of Femoral and Patellar Articular Cartilage Lesions of the Knee
Ganesh Cherala IRB00009569 Prenatal growth programs oral contraceptive metabolism and effectiveness
Richard Maziarz IRB00009571 A Phase II, Randomized Trial of Standard of Care with or without Midostaurin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients with FLT3-ITD Mutated Acute Myeloid Leukemia
Richard Maziarz IRB00009585 Prospective Multi-Center Cohort for the Evaluation of Biomarkers Predicting Risk of Complications and Mortality Following Allogeneic HCT
Stephen Heitner IRB00009594 Cardiovascular Inflammation Reduction Trial (CIRT)
Fay Horak IRB00009616 Balance Deficits in Multiple Sclerosis and Cerebellar Dysfunction
Saurabh Gupta IRB00009621 An Open-label, Randomized, Controlled, Multicenter Study Exploring Two Treatment Strategies of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention: PIONEER AF-PCI
Jeremy Cetnar IRB00009657 NP28761: A Phase I/II Study of the ALK Inhibitor CH5424802/RO5424802 in Patients with ALK-Rearranged Non-Small Cell Lung Cancer Previously Treated with Crizotinib
Atulya Deodhar IRB00009690 A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of Tofacitinib in Subjects with Active Ankylosing Spondylitis (AS)
Lynn Jansen IRB00009697 Understanding parental (and adolescent) risk/benefit assessments in research
John Morrison IRB00009729 Longitudinal observational study using functional and structural optical coherence tomography to diagnose and guide treatment of glaucoma
Michael Heinrich IRB00009741 A phase II randomized, multicenter study of treatment-free remission in chronic myeloid leukemia in chronic phase (CML-CP) Patients who achieve and sustain MR4.5 after switching to nilotinib
Garet Lahvis IRB00009747 Oregon Animation Test for Social Reciprocity (OATS)
Emma Scott IRB00009761 A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma.
Peter Jacobs IRB00009763 Efferent Suppression of Speech-Evoked OAEs: Implications in Aural Rehab
Penelope Hogarth IRB00009793 Fox Investigation for New Discovery of Biomarkers (BioFIND)
Michael Shapiro IRB00009813 International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA)
Lucinda Hugos IRB00009814 PVAMC / OHSU D: A Randomized Trial of Two Formal Group Programs for Multiple Sclerosis
Amira Al-Uzri IRB00009828 Designing a Convenient and Precise Device for Home Dried Blood Spot Collection
James Mudd IRB00009861 A Double-blind, Randomized, Placebo-controlled, Multicenter, Dose Escalation Study to Select and Evaluate an Oral Modified Release Formulation of Omecamtiv Mecarbil in Subjects with Heart Failure and Left Ventricular Systolic Dysfunction / Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF)
Lynne Shinto IRB00009880 Omega 3 PUFA for the vascular component of age-related cognitive decline
Akram Khan IRB00009885 Safety and Efficacy of A Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis IM136003
Julie Graff IRB00009892 PVAMC / OHSU J: A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer
Rachel Cook IRB00009893 S1203: A Randomized Phase III Study of Standard Cytarabine plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) versus IA with Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)
Morgan Hakki IRB00009894 A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Protective Efficacy and Safety of a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)
William Gregory IRB00009924 Real-time Observation of Safety and Effectiveness in the Treatment of Female Stress Urinary Incontinence
Neil Gross IRB00009925 Phase 2 Study to Evaluate the Pharmacokinetics and Drug-Drug Interaction of Cetuximab and Carboplatin in Patients with Recurrent or Metastatic Carcinoma of the Head and Neck
Emma Scott IRB00009936 A Multicenter, Randomized, Open-Label, Phase 2 Study of Carfilzomib With or Without ARRY-520 in Patients with Advanced Multiple Myeloma
Fay Horak IRB00009937 PVAMC / OHSU J: The Effect of Levodopa on Postural Motor Learning in Parkinson Disease
Jeffrey Jensen IRB00010023 A phase IIb randomized, double blind, comparative study to assess the efficacy, safety, tolerability and inhibition of ovulation of two continuous regimens of oral daily 5 mg or 10 mg of ulipristal acetate (UPA), versus a dose of 5.0mg UPA for 24/4 days
Jeremy Cetnar IRB00010028 Phase 2 Study of VS-6063, a Focal Adhesion Kinase (FAK) Inhibitor, in Patients with KRAS Mutant Non-Small Cell Lung Cancer
Cong-Qiu Chu IRB00010053 A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment with Disease-Modifying Antirheumatic Drugs
Robert Martindale IRB00010062 A Prospective, Multi-Center Study of Phasix™ Mesh for Ventral or Incisional Hernia Repair
Steven Shea IRB00010101 Circadian rhythms and cardiovascular risk
Jeffrey Jensen IRB00010103 Tubal patency during the menstrual cycle and during treatment with hormonal contraceptives: a pilot study in women
Neil Swanson IRB00010106 Safety and efficacy of escalating doses of ingenol mebutate once daily for two or three consecutive days when used on full face, full balding scalp or approximately 250 cm2 on the chest in subjects with actinic keratosis Part 1: A Phase 1, multicentre, open-label, dose escalation 2-week trial Part 2: A Phase 2, multicentre, randomised, double-blind, parallel group, vehicle-controlled, 8-week trial
Andrew Ahmann IRB00010114 YSI Feasibility Study of the Dexcom CGM System in Adults and Pediatrics with Diabetes Mellitus
Matthew Taylor IRB00010122 CBKM120ZUS40: Modular Phase 2 Study to Link Targeted Therapy to Patients with Pathway Activated Tumors: Module 1 - BKM120 for Patients with PI3K-activated Tumors
Andy Chen IRB00010123 An Open-Label, Phase I, Dose-Escalation Study Evaluating the Safety and Tolerability of GDC-0853 in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
Eric Simpson IRB00010144 A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Efficacy of CIM331 In Atopic Dermatitis Patients Who Are Inadequately Controlled by or Intolerant to Topical Therapy
Richard Maziarz IRB00010146 A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Intermediate-2 and High Risk Myelodysplastic Syndrome
Paul Spellman IRB00010163 Reconstructing the Tumor Genome in Peripheral Blood
Lucinda Hugos IRB00010164 PVAMC / OHSU J: Developing and Testing a Comprehensive MS Spasticity Management Program
Christopher Ryan IRB00010170 A Study of the Safety and Efficacy of the Combination of Gemcitabine and Docetaxel with MORAb-004 in Metastatic Soft Tissue Sarcoma
Matthew Taylor IRB00010177 A Phase I, Open-Label, Multiple-Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects with Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Kevin Winthrop IRB00010178 Safety and Effectiveness of the Live Zoster Vaccine in Anti-TNF Users (VERVE Trial)
Cailin Sibley IRB00010209 ACR/EULAR endorsed study to develop classification and diagnostic criteria for primary systemic vasculitis
Elie Traer IRB00010224 A Phase II Open-Label, Single-Arm, Two Stage, Multicenter Trial of Pracinostat in Combination With Azacitidine in Elderly (Age ≥ 65 Years) Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
Katharine Simmons IRB00010228 Tamoxifen for the treatment of unfavorable bleeding patterns in Etonogestrel contraceptive implant users
Joshi Alumkal IRB00010241 Molecular Mechanisms Underlying Tumor Progression Despite Enzalutamide Treatment
Neha Garg IRB00010253 PROMIS in Rheumatology
Kim-Hien Dao IRB00010262 Prospective Evaluation of ruxolitinib Efficacy for CNL/aCML Patients with Mutation of CS3FR
Deniz Erten-Lyons IRB00010264 Protocol H8A-MC-LZAZ(a)/ADC-040-A4 Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4 Study)
Andy Chen IRB00010274 A Phase Ib Study Evaluating the Safety, Tolerability and Anti-Tumor Activity of DCDS4501A in Combination with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients with B-Cell Non-Hodgkin’s Lymphoma
Scott Chadderdon IRB00010299 Physical Activity and Obesity: The Role of Nitric Oxide and Eicosanoids in Regulating Capillary Perfusion and Vascular Insulin Resistance
Benjamin Ehst IRB00010330 A Trial to Determine the Effect of Psoriasis Treatment on Cardiometabolic Disease
Xin Li IRB00010345 Contrast Enhanced MRI of the Prostate
Michael Shapiro IRB00010361 CAscade SCreening for Awareness and DEtection of Familial Hypercholesterolemia (CASCADE FH Registry)
Stephen Heitner IRB00010369 A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ISIS 420915 in Patients with Familial Amyloid Polyneuropathy (ISIS 420915-CS2 FAP)
Laura Carim Todd IRB00010373 Behavioral Interventions to Target Self-Control
Sara Walker IRB00010379 Prospective Investigation of the Quality of Life, Emotional Functioning, and Treatment Satisfaction among Patients in Radiation Medicine
Stephen Spurgeon IRB00010383 A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-Lag-3 (BMS-986016) in Relapsed or Refractory Chronic Lymphocytic Leukemia and Lymphomas
Andrew Ahmann IRB00010415 Severe Hypoglycemia in Older Adults with Type 1 Diabetes: A Study to Identify Factors Associated with the Occurrence of Severe Hypoglycemia in Older Adults with T1D.
Matthew Taylor IRB00010426 Modular Phase 2 Study to Link Targeted Therapy to Patients with Pathway Activated Tumors: Module 3 - MEK162 for Patients with RAS/RAF/MEK Activated Tumors
Matthew Taylor IRB00010427 [Quroum] Modular Phase II Study to Link Targeted Therapy to Patients with Pathway Activated Tumors: Module 4 - LGX818 for Patients with BRAFV600E Mutated Tumors
Andrew Ahmann IRB00010497 A randomized, 30 week, active-controlled, open-label, 3-treatment arm, parallel-group multicenter study comparing the efficacy and safety of insulin glargine/lixisenatide fixed ratio combination to insulin glargine alone and to lixisenatide alone on top of metformin in patients with Type 2 diabetes mellitus (T2DM)
Donna Graville IRB00010500 Communication, Health, Aging, Relationship Types and Support
Stephen Chui IRB00010502 A Randomized Placebo-Controlled Phase III Study of Duloxetine for Treatment of Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Women with Early Stage Breast Cancer
Frederick Tibayan IRB00010527 A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Preoperative Antithrombin Supplementation in Patients Undergoing High-Risk Cardiac Surgery with Cardiopulmonary Bypass (GTI-1307)
Lara Davis IRB00010529 SARC024: A blanket protocol to study oral regorafenib in patients with refractory liposarcoma, osteogenic sarcoma, and Ewing/Ewing–like sarcomas
Steven Bailey IRB00010535 Optical coherence tomography angiography in neovascular age-related macular degeneration
Michael Heinrich IRB00010537 A Phase I, Multicenter, Open-Label Study of Oral ABL001 in Patients with Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Charles Lopez IRB00010540 A Phase III, Multicenter, Open-Label, Randomized Study of nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects with Surgically Resected Pancreatic Adenocarcinoma
Kimberly Mauer IRB00010548 Functional Imaging of Light-Induced Activation of Pain-Related Circuitry in Fibromyalgia as a Marker for Central Sensitization
Sancy Leachman IRB00010561 War on Melanoma: Enlisting a cohort of melanoma survivors and their families
Lynne Shinto IRB00010569 Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis
Jon Hanifin IRB00010579 Validation of ItchyQuant, A self-reported itch severity scale. “Validation and Mobilization of Pediatric Pruritus Outcome Instruments”
Julie Graff IRB00010586 A three arm randomized, open-label Phase II study of radium-223 dichloride 50 kBq/kg versus 80 kBq/kg, and versus 50 kBq/kg in an extended dosing schedule in subjects with castration-resistant prostate cancer metastatic to the bone
Rebecca Spain IRB00010599 Aerobic exercise to improve brain metabolism in MS
Kathleen Wilder IRB00010604 A randomized, parallel-group, double-blind, placebo-controlled, multi-center study to assess the efficacy and safety of different doses of BAY 1002670 in subjects with uterine fibroids over 3 months
Matthew Taylor IRB00010605 A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 under Adaptable Dosing Schedules in Patients with Advanced Solid Malignancies
Stephen Heitner IRB00010645 A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects with Symptomatic Hypertrophic Cardiomyopathy (GS-US-361-1157)
Matthew Taylor IRB00010653 Module Phase II Study to Link Targeted Therapy to Patients with Pathway Activated Tumors: Module 2 - Dovitinib for Patients with Tumor Pathway Activations Inhibited by Dovitinib Including Tumors with Mutations or Translocations of FGFR, PDGFR, VEGF, cKIT, FLT3, CSFR1, Trk and RET
Christopher Ryan IRB00010659 A Multicenter, Randomized, Open-Label Phase 3 Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Investigator’s Choice in Subjects with Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcomas Who Either Relapsed or Were Refractory to Prior Non-Adjuvant Chemotherapy
Stephen Heitner IRB00010707 Novel Predictors of Outcome in Hypertrophic Cardiomyopathy (HCMR)
John Nutt IRB00010745 Effects of augmenting cholinergic function on gait and balance
Patricia Carlson-Kuhta IRB00010775 Monitoring Balance and Gait Disorders in Parkinson’s Disease with the Home Objective Mobilty Exam (HOME)
Helane Wahbeh IRB00010939 Internet Mindfulness Meditation Intervention (IMMI)
John Hunter IRB00010973 Laparoscopic Nissen Fundoplication (LNF) Surgery Versus Transoral Incisionless Fundoplication (TIF): Anti- Reflux Treatment Registry (STAR registry)
 
For more information:
Email: trials@ohsu.edu
Call: 503-494-1080
 

You may qualify for additional trials within our Phase 1 Program